文献速递脊柱关节炎

银屑病关节炎治疗良好应答者的影像学进展:新型复合疾病活动度指数的数据

Radiographic Progression in Psoriatic Arthritis Achieving a Good Response to Treatment: Data Using Newer Composite Indices of Disease Activity.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2018-04-12

基于GO-REVEAL数据集,比较PASDAS、GRACE和DAPSA三种复合指标评估的应答程度与24周影像学进展的关系。结果显示,良好应答组影像学进展显著更少,PASDAS和GRACE分层下无进展比例分别为83%和80%,DAPSA为76%(P=0.19)。

要点

  • 良好应答者影像学进展显著少于中等或差应答者。
  • PASDAS良好应答组83%无影像学进展(P=0.02)。
  • GRACE良好应答组80%无进展(P=0.05),DAPSA为76%(P=0.19)。

核心结论

  • 疾病特异性复合指标的应答标准可区分影像学进展不同的组别,可作为干预研究和临床目标。

研究设计与样本

  • 数据来自GO-REVEAL随机双盲研究,评估两种剂量戈利木单抗治疗活动性银屑病关节炎的安全性和疗效。
  • 在第24周应用应答标准于整个数据集,不考虑治疗分组。
  • 基线和24周影像学评分采用改良Sharp/van der Heijde法评估。

主要发现

  • 每种指标下,中等或差结局者的影像学进展显著更大,良好结局者无进展。
  • PASDAS良好结局组无影像学进展比例为83%(χ2=7.9;P=0.02)。
  • GRACE良好结局组无进展比例为80%(χ2=5.8;P=0.05)。
  • DAPSA良好结局组无进展比例为76%(χ2=3.4;P=0.19)。

关键数值与推荐

  • PASDAS良好应答组83%无影像学进展(P=0.02)。
  • GRACE良好应答组80%无影像学进展(P=0.05)。
  • DAPSA良好应答组76%无影像学进展(P=0.19)。

临床怎么用

  • 临床中可将PASDAS、GRACE或DAPSA的良好应答作为治疗目标,以降低影像学进展风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare radiographic outcomes according to the magnitude of the response utilizing 3 new psoriatic composite disease activity measures (the Psoriatic Arthritis Disease Activity Score [PASDAS], the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis Composite Exercise [GRACE], and the Disease Activity in PsA [DAPSA]). METHODS: The data were taken from the GO-REVEAL data set, a large randomized, double-blind study that evaluated the safety and efficacy of 2 doses of the tumor necrosis factor inhibitor golimumab in subjects with active psoriatic arthritis (PsA). Response criteria at 24 weeks were applied across the whole data set, irrespective of treatment group. Radiographic scores at baseline and 24 weeks were assessed using the modified Sharp/van der Heijde method for PsA. RESULTS: Overall, for each measure, radiographic progression was significantly greater in subjects with a moderate or poor outcome, and absent in those with a good outcome. The proportion of subjects without radiographic progression in the good outcome group was 83% using the PASDAS (χ2 = 7.9; P = 0.02), 80% using the GRACE (χ2 = 5.8; P = 0.05), and 76% using the DAPSA (χ2 = 3.4; P = 0.19). CONCLUSION: Response criteria for disease-specific composite measures enable separation between groups in terms of radiographic progression and may therefore be used as suitable targets for interventional studies, as well as in the clinic.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Helliwell PS, Kavanaugh A. Radiographic Progression in Psoriatic Arthritis Achieving a Good Response to Treatment: Data Using Newer Composite Indices of Disease Activity. Arthritis Care Res (Hoboken). 2018. PMID: 28834259. doi:10.1002/acr.23345

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。